Browsing Tag

ATRC101

Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor…

Eli Pacheco May 5, 2022 0

SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated…

Health

Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data…

Eli Pacheco Mar 4, 2022 0

Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial Clinical…

Health

Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of…

Eli Pacheco Jul 27, 2021 0

SAN CARLOS, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated…